CoChat

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil

Open access
Cerqueira-Silva, Thiago, Katikireddi, Srinivasa Vittal, de Araujo Oliveira, Vinicius, Flores-Ortiz, Renzo, Júnior, Juracy Bertoldo, Paixão, Enny S., Robertson, Chris, Penna, Gerson O., Werneck, Guilherme L., Barreto, Maurício L., Pearce, Neil, Sheikh, Aziz, Barral-Netto, Manoel, Boaventura, Viviane S. · 2022 · Nature Medicine
Cited by 121

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of BNT162b2 booster vaccination against RT–PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death). Compared with unvaccinated individuals, CoronaVac VE at 14–30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3–55.7) against confirmed infection and 82.1% (95% CI: 81.4–82.8) against severe outcomes. VE decreased to 34.7% (95% CI: 33.1–36.2) against infection and 72.5% (95% CI: 70.9–74.0) against severe outcomes over 180 d after the second dose. A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0−94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1−98.1) 14–30 d after the booster. Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster. Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01701-w

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 121

Metadata

Authors
Cerqueira-Silva, T., Katikireddi, S. V., de Araujo Oliveira, V., Flores-Ortiz, R., Júnior, J. B., Paixão, E. S., Robertson, C., Penna, G. O., Werneck, G. L., Barreto, M. L., Pearce, N., Sheikh, A., Barral-Netto, M., & Boaventura, V. S.
Venue
Nature Medicine
Published
2022-02-09
Volume
28
Issue
4
Pages
838-843
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4210844692
Cited by
121
References
5
FWCI
13.38
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. https://app.cochat.ai/papers/10.1038/s41591-022-01701-w
The paper
Cerqueira-Silva, T., Katikireddi, S. V., de Araujo Oliveira, V., Flores-Ortiz, R., Júnior, J. B., Paixão, E. S., Robertson, C., Penna, G. O., Werneck, G. L., Barreto, M. L., Pearce, N., Sheikh, A., Barral-Netto, M., & Boaventura, V. S. (2022). Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nature Medicine. https://doi.org/10.1038/s41591-022-01701-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.